Impaired unsaturated fatty acid elongation alters mitochondrial function and accelerates metabolic dysfunction-associated steatohepatitis progression.

Fiche publication

Date publication

octobre 2024

Journal

Metabolism: clinical and experimental

Auteurs

Membres identifiés du Cancéropôle Est :
Dr RIALLAND Mickaël , Dr PAIS DE BARROS Jean-Paul , Pr MASSON David

Tous les auteurs :
Vouilloz A, Bourgeois T, Diedisheim M, Pilot T, Jalil A, Le Guern N, Bergas V, Rohmer N, Castelli F, Leleu D, Varin A, de Barros JP, Degrace P, Rialland M, Blériot C, Venteclef N, Thomas C, Masson D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39454822

Résumé

Although qualitative and quantitative alterations in liver Polyunsaturated Fatty Acids (PUFAs) are observed in MASH in humans, a causal relationship of PUFAs biosynthetic pathways is yet to be clarified. ELOVL5, an essential enzyme in PUFA elongation regulates hepatic triglyceride metabolism. Nonetheless, the long-term consequences of elongase disruption, particularly in murine models of MASH, have not been evaluated.